2018
DOI: 10.1038/sdata.2018.275
|View full text |Cite
|
Sign up to set email alerts
|

Transcript- and protein-level analyses of the response of human eosinophils to glucocorticoids

Abstract: Glucocorticoids are first-line agents for the treatment of many eosinophil-associated disorders; however, their effects on human eosinophils remain poorly understood. To gain an unbiased, genome-wide view of the early transcriptional effects of glucocorticoids on human eosinophils in vivo, RNA sequencing was performed on purified blood eosinophils obtained before and 30, 60, and 120 minutes after administration of a single dose of oral prednisone (1 mg/kg) to three unrelated healthy subjects with hypereosinoph… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 21 publications
(23 reference statements)
0
4
0
Order By: Relevance
“…Cells were grown in 384-well plates (CellCarrier Ultra 384; PerkinElmer, Waltham, MA), fixed in 4% paraformaldheyde (PFA) and stained with 4 0 , 6 0 -diamidino-2-phenylindole (DAPI). Primary human eosinophils were obtained from healthy donors enrolled under NIH protocol NCT000090662 and purified as previously described (17). The protocol was approved by the Institutional Review Board of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).…”
Section: Methodsmentioning
confidence: 99%
“…Cells were grown in 384-well plates (CellCarrier Ultra 384; PerkinElmer, Waltham, MA), fixed in 4% paraformaldheyde (PFA) and stained with 4 0 , 6 0 -diamidino-2-phenylindole (DAPI). Primary human eosinophils were obtained from healthy donors enrolled under NIH protocol NCT000090662 and purified as previously described (17). The protocol was approved by the Institutional Review Board of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).…”
Section: Methodsmentioning
confidence: 99%
“…Briefly, GC dampen neutrophil response to inflammatory stimuli ( 379 ), increase susceptibility to viral as well as opportunistic infections inducing lymphopenia (mainly of the CD4 + subset) by altering CD4/CD8 ( 380 ) and Th1/Th2 ratio subpopulations ( 381 ), suppress cytotoxic activity in natural killer cells ( 382 ), reduce eosinophil count ( 383 ), and reduce mast-cells interfering with IgE-mediated mast-cell degranulation and calcium release ( 384 ). Interestingly, some of these effects seem to be dose dependent and different in exogenous vs endogenous GC excess ( 375 ).…”
Section: The Adverse Effects Of Prescribed Gcsmentioning
confidence: 99%
“…Cells were grown in 384-well plates (CellCarrier Ultra 384, PerkinElmer, Waltham, MA), fixed in 4% PFA and stained with DAPI. Primary human eosinophils were obtained from healthy donors enrolled under NIH protocol NCT000090662 and purified as previously described (17). Eosinophils were plated in Poly-D-Lysine coated 384-well plates (CellCarrier Ultra 384, PerkinElmer, Waltham, MA), then fixed in 4% PFA and stained with DAPI.…”
Section: Cellsmentioning
confidence: 99%